Table 3. Reasons for extension of treatment beyond 6 months.

Treatment regimens	INH low concentrationresistance, n = 44	INH high concentrationresistance, n = 90	Odds ratio(95% CI)	p value
Pyrazinamide given for <6 months, all	19(47.5%)	32(41.0%)	1.30(0.60–2.80)	0.502
Because of physician preference	3(7.5%)	6(7.7%)	0.97(0.23–4.11)	0.970
Because of adverse reaction	16(40.0%)	26(33.3%)	1.33(0.61–2.93)	0.474
Hepatotoxicity	8(20.0%)	8(10.3%)	2.19(0.75–6.35)	0.143
Hyperuricemia/gout	8(20.0%)	16(20.5%)	0.97(0.37–2.51)	0.948
Rash	0(0%)	2(2.6%)	0.38(0.02–8.06)	0.307
Treatment noncompliance	2(5.0%)	3(3.8%)	1.32(0.21–8.22)	0.768
Extrapulmonary tuberculosis	5(12.5%)	4(5.1%)	2.64(0.67–10.46)	0.153
Delayed clinical response to treatment	8(20.0%)	24(30.8%)	0.56(0.23–1.40)	0.213
Delayed culture conversion	6(15.0%)	15(19.2%)	0.74(0.26–2.09)	0.570

Abbreviations: INH: isoniazid; CI: confidence interval.